Results 231 to 240 of about 843,559 (297)

Efficacy and Safety of Datopotamab Deruxtecan From a Single‐Institution Experience in Hormone Receptor–Positive, HER2‐Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody–Drug Conjugates

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell surface antigen 2 (TROP2)–directed antibody–drug conjugate (ADC) with a topoisomerase I inhibitor payload and was approved by the Japan Pharmaceuticals and Medical Devices Agency in 2025 for patients with unresectable or recurrent hormone receptor–positive (HR+)/human epidermal
Hiroko Shimada   +18 more
wiley   +1 more source

Preclinical evaluation of SLC35D3-targeted CAR-T cells for tumor-selective immunotherapy. [PDF]

open access: yesBiochem Biophys Rep
Someya S   +5 more
europepmc   +1 more source

M11‐CAR T cells inhibit murine cytomegalovirus in vitro upon recognition of virion‐ and cell‐associated glycoprotein B

open access: yesClinical &Translational Immunology, Volume 15, Issue 11, 2026.
Abstract Objectives Viral infections are predominantly managed with conventional antiviral drugs, which, despite their efficacy, can cause toxicity and promote resistance. Cell‐based immunotherapies offer an alternative, but cytomegaloviruses (CMV) profoundly interfere with MHC class I antigen presentation, thereby impairing conventional virus‐specific
Sabrina Kübel   +14 more
wiley   +1 more source

Type-II-CD20-targeted therapy for CD38 antibody-refractory antibody-mediated rejection after kidney transplantation: a case report. [PDF]

open access: yesFront Immunol
de Fallois J   +10 more
europepmc   +1 more source

Plant Molecular Farming for Cancer Immunotherapy: Production, Glycoengineering, and Structural Insights into Therapeutic Monoclonal Antibodies. [PDF]

open access: yesCurr Issues Mol Biol
Tamayo-Ordoñez MC   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy